However, long-term experience and specific clinical trials have revealed several limitations of tamoxifen in the adjuvant setting, including limited duration of effectiveness, continuing risk of ...
Boston, MA, and San Francisco, CA - The aromatase inhibitors have revolutionized breast-cancer treatment by providing a more effective alternative to tamoxifen. However, Drs David T Felson (Boston ...
Researchers found that 44.8% of the 357 patients exhibited coronary artery calcium; groups had no significant difference in aromatase inhibitor treatment duration. HealthDay News — For postoperative ...
In this analysis of the phase 3 ALLTO trial, researchers explored 10-year outcomes of HR+, HER2+ early breast cancer patients who received either an aromatase inhibitor or a selective estrogen ...
Aromatase inhibitors (AIs) represent a cornerstone in the treatment of oestrogen receptor–positive breast cancer, particularly among postmenopausal women. Although these drugs have substantially ...
Learn Look Locate and Walgreens Expand Breast Cancer Education with New Aromatase Inhibitor Resource
Learn Look Locate (LLL), a global leader in breast cancer education and patient support, is proud to announce the launch of a groundbreaking new educational webpage on aromatase inhibitors in ...
SurvivorNet on MSN
Major New Drug Approval For Preventing Recurrence In Early Stage Breast Cancer Patients: Weighing The Risks & Benefits of Kisqali
In a long awaited approveall, The Food and Drug Administration (FDA) has just approved the drug Kisqali (ribociclib) in ...
Alpelisib/Fulvestrant combo improves OS, PFS for patients with previously-treated PIK3CA-Mutated, HR+, HER2− advanced breast cancer ...
ByEllis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol. 2008, 26(30):4875-4882. doi: ...
Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset. For patients with hormone receptor ...
DEAR DR. ROACH: I am an 80-year-old female and a 25-year survivor of ovarian cancer. In the past three years, I have also had Merkel cell cancer, breast cancer, and now squamous cell cancer on my lip.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback